Methylated DNA and total DNA in serum detected by one-step methylation-specific pcr is predictive of poor prognosis for breast cancer patients

Oncology (Switzerland)

Volumn 83, Issue 5, 2012, Pages 273-282

  Fujita, Noriko ^a   Nakayama, Takahiro ^a   Yamamoto, Noriaki ^b   Kim, Seung Jin ^a   Shimazu, Kenzo ^a   Shimomura, Atsushi ^a   Maruyama, Naomi ^a   Morimoto, Koji ^a   Tamaki, Yasuhiro ^a   Noguchi, Shinzaburo ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b SYSMEX CORPORATION   (Japan)

Author keywords

Breast cancer; DNA; Methylation; Prognosis; Serum

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE P1; PROGESTERONE RECEPTOR; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DNA CONTENT; DNA METHYLATION; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INVASIVE LUNG CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METHYLATION SPECIFIC POLYMERASE CHAIN REACTION; OVERALL SURVIVAL; PARTIAL MASTECTOMY; POLYMERASE CHAIN REACTION; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; ANALYSIS OF VARIANCE; BASE SEQUENCE; BREAST NEOPLASMS; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; LYMPHATIC METASTASIS; MASTECTOMY; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM GRADING; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROMOTER REGIONS, GENETIC; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECEPTORS, RETINOIC ACID; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84865853256     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000342083     Document Type: Article

References (35)

1. Paik S: Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007; 12: 631-635.
2. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH: Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415: 530-536.
3. Suijkerbuijk KP, van Diest PJ, van der Wall E: Improving early breast cancer detection: focus on methylation. Ann Oncol 2010; 22: 24-29.
4. Brooks J, Cairns P, Zeleniuch-Jacquotte A: Promoter methylation and the detection of breast cancer. Cancer Causes Control 2009; 20: 1539-1550.
5. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 2003; 63: 7641-7645.
6. Gobel G, Auer D, Gaugg I, Schneitter A, Lesche R, Muller-Holzner E, Marth C, Daxenbichler G: Prognostic significance of methylated RASSF1A and PITX2 genes in bloodand bone marrow plasma of breast cancer patients. Breast Cancer Res Treat 2011; 130: 109-117.
7. Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, Pandya P, Ralhan R: Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. Life Sci 2010; 87: 83-91.
8. Lo PK, Sukumar S: Epigenomics and breast cancer. Pharmacogenomics 2008; 9: 1879-1902.
9. Martens JW, Margossian AL, Schmitt M, Foekens J, Harbeck N: DNA methylation as a biomarker in breast cancer. Future Oncol 2009; 5: 1245-1256.
10. Brock MV, Hooker CM, Ota-Machida E, Han Y, Guo M, Ames S, Glockner S, Piantadosi S, Gabrielson E, Pridham G, Pelosky K, Belinsky SA, Yang SC, Baylin SB, Herman JG: DNA methylation markers and early recurrence in stage I lung cancer. N Engl J Med 2008; 358: 1118-1128.
11. Ponomareva AA, Rykova E, Cherdyntseva NV, Skvortsova TE, Dobrodeev A, Litviakov NV, Zav'ialov AA, Tuzikov SA, Vlasov VV, Laktionov PP: [Assay of methylated gene RARBETA2 in circulating DNA of blood from patients with lung cancer as a potential prognostic marker]. Vopr Onkol 2011; 57: 302-307.
12. Lofton-Day C, Model F, Devos T, Tetzner R, Distler J, Schuster M, Song X, Lesche R, Liebenberg V, Ebert M, Molnar B, Grutzmann R, Pilarsky C, Sledziewski A: DNA methylation biomarkers for blood-based colorectal cancer screening. Clin Chem 2008; 54: 414-423.
13. Shima K, Nosho K, Baba Y, Cantor M, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S: Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. Int J Cancer 2011; 128: 1080-1094.
14. Dulaimi E, Hillinck J, Ibanez de Caceres I, Al-Saleem T, Cairns P: Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. Clin Cancer Res 2004; 10: 6189-6193.
15. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, Sukumar S: Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 2004; 64: 4442-4452.
16. Fiegl H, Millinger S, Mueller-Holzner E, Marth C, Ensinger C, Berger A, Klocker H, Goebel G, Widschwendter M: Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res 2005; 65: 1141-1145.
17. Hoque MO, Feng Q, Toure P, Dem A, Critchlow CW, Hawes SE, Wood T, Jeronimo C, Rosenbaum E, Stern J, Yu M, Trink B, Kiviat NB, Sidransky D: Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J Clin Oncol 2006; 24: 4262-4269.
18. Grunau C, Clark SJ, Rosenthal A: Bisulfite genomic sequencing: systematic investigation of critical experimental parameters. Nucleic Acids Res 2001; 29:E65-E65.
19. Hayatsu H, Shiraishi M, Negishi K: Bisulfite modification for analysis of DNA meth-ylation. Curr Protoc Nucleic Acid Chem 2008;Chapter 6:Unit 6.10.
20. Yamamoto N, Nakayama T, Kajita M, Miyake T, Iwamoto T, Kim SJ, Sakai A, Ishihara H, Tamaki Y, Noguchi S: Detection of aberrant promoter methylation of GSTP1, RASSF1A, and RAR-2 in serum DNA of patients with breast cancer by a newly established one-step methylation-specific PCR assay. Breast Cancer Res Treat 2012; 132: 165-173.
21. Gal S, Fidler C, Lo YM, Taylor M, Han C, Moore J, Harris AL, Wainscoat JS: Quantitation of circulating DNA in the serum of breast cancer patients by real-time PCR. Br J Cancer 2004; 90: 1211-1215.
22. Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W, Zhong XY: Positive correlation of cell-free DNA in plasma/ serum in patients with malignant and benign breast disease. Anticancer Res 2008; 28: 921-925.
23. Huang ZH, Li LH, Hua D: Quantitative analysis of plasma circulating DNA at diagnosis and during follow-up of breast cancer patients. Cancer Lett 2006; 243: 64-70.
24. Schwarzenbach H, Muller V, Milde-Langosch K, Steinbach B, Pantel K: Evaluation of cell-free tumour DNA and RNA in patients with breast cancer and benign breast disease. Mol Biosyst 2011; 7: 2848-2854.
25. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Senn HJ: Meeting highlights: international consensus panel on the treatment of primary breast cancer. Seventh international conference on adjuvant therapy of primary breast cancer. J Clin Oncol 2001; 19: 3817-3827.
26. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ: Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003; 21: 3357-3365.
27. Arai T, Miyoshi Y, Kim SJ, Taguchi T, Tamaki Y, Noguchi S: Association of GSTP1 CPG islands hypermethylation with poor prognosis in human breast cancers. Breast Cancer Res Treat 2006; 100: 169-176.
28. Robbins P, Pinder S, de Klerk N, Dawkins H, Harvey J, Sterrett G, Ellis I, Elston C: Histological grading of breast carcinomas: a study of interobserver agreement. Hum Pathol 1995; 26: 873-879.
29. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS: Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 2008; 10:R46.
30. Van der Auwera I, Elst HJ, Van Laere SJ, Maes H, Huget P, van Dam P, Van Marck EA, Vermeulen PB, Dirix LY: The presence of circulating total DNA and methylated genes is associated with circulating tumour cells in blood from breast cancer patients. Br J Cancer 2009; 100: 1277-1286.
31. Matuschek C, Bolke E, Lammering G, Gerber PA, Peiper M, Budach W, Taskin H, Prisack HB, Schieren G, Orth K, Bojar H: Methylated APC and GSTP1 genes in serum DNA correlate with the presence of circulating blood tumor cells and are associated with a more aggressive and advanced breast cancer disease. Eur J Med Res 2010; 15: 277-286.
32. Schwarzenbach H, Hoon DS, Pantel K: Cellfree nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011; 11: 426-437.
33. Fleischhacker M, Schmidt B: Circulating nucleic acids (CNAs) and cancer-a survey. Biochim Biophys Acta 2007; 1775: 181-232.
34. Kowalewska M, Nowak R, Chechlinska M: Implications of cancer-associated systemic inflammation for biomarker studies. Biochim Biophys Acta 2010; 1806: 163-171.
35. Schwarzenbach H, Alix-Panabieres C, Muller I, Letang N, Vendrell JP, Rebillard X, Pantel K: Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 2009; 15: 1032-1038.